Acute myelogenous leukemia
What is acute myeloid leukemia?
Acute myeloid leukemia (AML) starts in the blood stem cells and develops quickly. It is the most common type of leukemia in adults.
Risk factors for acute myelogenous leukemia (AML)
Risks for acute myelogenous leukemia (AML) include genetic syndromes, high doses of radiation and smoking. Learn about AML risk.
Diagnosis of leukemia
Tests to diagnose leukemia, such as blood tests and imaging tests, are done when symptoms or routine tests suggest a problem. Learn about diagnosing leukemia.
Stages of acute myeloid leukemia
The stage describes how much cancer is in the body. Acute myeloid leukemia (AML) is described as untreated, active disease, in remission, measurable residual disease (MRD), relapsed or refractory.
Disease progression of acute myeloid leukemia
Cancer cells can spread from where they start to other parts of the body. Acute myeloid leukemia (AML) is often widespread when it is found.
Prognosis and survival for acute myeloid leukemia
Prognosis estimates the outcome for acute myeloid leukemia (AML). It depends on many factors including subtype, chromosome changes and your age.
Treatments for acute myeloid leukemia
Chemotherapy is the main treatment for acute myeloid leukemia (AML). Targeted therapy and a stem cell transplant may also be used.
Supportive care for leukemia
Supportive care helps people with physical, practical and emotional aspects of leukemia. Learn how to cope with long-term effects of leukemia.
Research in acute myelogenous leukemia (AML)
We are always learning more about cancer. Researchers and healthcare professionals use what they learn from research studies to develop better practices that will help find and treat acute myelogenous leukemia (AML). They are also looking for ways to improve the quality of life of people with AML.
Acute myelogenous leukemia statistics
Acute myelogenous leukemia (AML) is a leading cause of adult leukemia deaths in Canada. Learn about incidence and mortality statistics for this cancer.